• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
BlackDoctor.org
Where Wellness & Culture Connect

Where Wellness & Culture Connect

  • Conditions
  • Wellness
  • Lifestyle
  • Longevity
  • Clinical Trials
  • Resources
    • Top Blacks in Healthcare 2025
    • Hall Of Fame
    • Clinical Trials Resource Center
    • Obesity Resource Center
    • Cancer Resource Center
    • Wellness on the Yard
    • Immunocompromised Care
    • BDO Resource Library
  • Find A Doctor
  • BDO TV
Home / Health Conditions / Clinical Trials / This Clinical Trial Showed Promise in Recurrent Prostate Cancer Patients

This Clinical Trial Showed Promise in Recurrent Prostate Cancer Patients

This Clinical Trial Showed Promise in Recurrent Prostate Cancer Patients

(HealthDay News) — For men with high-risk biochemically recurrent prostate cancer, olaparib monotherapy yields good prostate-specific antigen (PSA) response rates, especially among those with BRCA2, according to a study published online Aug. 22 in JAMA Oncology.

Catherine H. Marshall, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the activity of olaparib monotherapy among patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy in a phase 2, single-arm nonrandomized controlled trial. A total of 51 male patients were enrolled and received treatment with olaparib twice daily until doubling of baseline PSA, clinical or radiographic progression, or unacceptable side effects.

The researchers found 13 participants (26 percent) had a 50 percent or higher decline in PSA from baseline (PSA50); all were within the homologous recombination repair-positive group (13 of 27; 48 percent). A PSA50 response occurred in all 11 participants with BRCA2 alterations. Fatigue, nausea, and leukopenia were common adverse events (63, 55, and 43 percent, respectively), which were consistent with known adverse effects of olaparib.

“Molecularly targeted therapies in select patient populations may be a reasonable treatment strategy for some patients with recurrent prostate cancer, even in the absence of androgen deprivation therapy,” the authors write.

Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which provided olaparib and financial support for the study.

What does this mean for men with prostate cancer?

This clinical trial is looking at a drug called olaparib from AstraZeneca to treat a type of prostate cancer called biochemically recurrent prostate cancer. This means the cancer has come back after surgery, even though there’s no evidence of it on scans.

How does olaparib work?

Olaparib is a type of drug that targets cancer cells. It works by stopping cancer cells from repairing themselves, which can lead to their death.

Who was in the study?

The study included men who had prostate cancer surgery and then experienced a recurrence. They had to have a certain level of a protein called PSA (prostate-specific antigen) in their blood.

What were the results of the trial?

Some men responded well: About half of the men with a specific genetic change called a BRCA2 alteration saw a significant decrease in their PSA levels. This suggests that olaparib might be effective for this group of patients.
Not everyone benefited: Men without the BRCA2 alteration didn’t see as much benefit from olaparib.
Side effects: The study also looked at the side effects of olaparib. Common side effects included fatigue, nausea, and low blood cell count.

The study shows that olaparib might be a promising treatment option for men with biochemically recurrent prostate cancer who have a BRCA2 alteration. However, more research is needed to confirm these findings and to understand how olaparib can be used most effectively in this setting.

What does this mean for Black men?

Black men are disproportionately affected by prostate cancer, and clinical trials like this can help address this disparity. By participating, they contribute to research that can lead to new treatments and improved outcomes. Clinical trials offer the opportunity to receive cutting-edge care and can help raise awareness about prostate cancer. Participating can empower Black men to take a proactive role in their own health and advocate for better health care access for their community.

Abstract/Full Text (subscription or payment may be required)

By Team BlackDoctor.org | Published August 26, 2024

August 26, 2024 by Team BlackDoctor.org

The Latest In Clinical Trials

lupus

Doctors Dismissed Her Symptoms—Then She Collapsed at a Work Conference

When Aleta was first diagnosed with lupus, she wasn’t ready to share her diagnosis with anyone beyond her closest family and friends. She wasn’t ashamed—far from it—but the idea of being treated differently made her uneasy. She didn’t want pity, read more about Doctors Dismissed Her Symptoms—Then She Collapsed at a Work Conference
How I Advocated For Myself to Join a Breast Cancer Clinical Trial

How I Advocated For Myself to Join a Breast Cancer Clinical Trial

When Latoya Bolds-Johnson, a then 37-year-old physician assistant and mother of three, was diagnosed with an aggressive form of breast cancer, she knew she needed to be her own best advocate. https://www.youtube.com/watch?v=TDlZ3XdxZZU&list=PLg8loYXuxhpxoACT8wJMAAITGZEN-Ym4c&index=2 Despite initially facing an oncologist who seemed disengaged read more about How I Advocated For Myself to Join a Breast Cancer Clinical Trial
This Study Reveals Why More People Aren't Doing Clinical Trials

This Study Reveals Why More People Aren’t Doing Clinical Trials

A new study, "The influence of socioeconomic status on individual attitudes and experience with clinical trials," published in Nature, sheds light on the significant disparities in clinical trial participation among different socioeconomic groups. The research highlights how factors such as read more about This Study Reveals Why More People Aren’t Doing Clinical Trials
Immunotherapy Works As Well In Senior Cancer Patients As In Younger Adults

Immunotherapy Works As Well In Senior Cancer Patients As In Younger Adults

It’s well-known that a person’s immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn’t appear to hinder the effectiveness of immunotherapy for cancer in seniors, a new study says. Seniors read more about Immunotherapy Works As Well In Senior Cancer Patients As In Younger Adults
weight loss drug

New Weight-Loss Drug Ecnoglutide Shows Bigger Results Than Others

While popular obesity and type 2 diabetes medications, such as Ozempic and Wegovy, have continued to grow in demand and usage across the U.S., there may be a new type on the horizon. Ozempic and Wegovy are semaglutide-based, meaning the read more about New Weight-Loss Drug Ecnoglutide Shows Bigger Results Than Others
prostate cancer, prostate cancer treatment, prostate cancer genetics, prostate cancer genomics

Genetics Aren’t Just Killing Black Men With Prostate Cancer, Poor Healthcare Is

A recent study published in JAMA Network Open looked at the genetic differences in prostate cancer between races. Researchers used data from over 5,000 military veterans with metastatic disease (meaning the cancer has spread from its original site) who underwent read more about Genetics Aren’t Just Killing Black Men With Prostate Cancer, Poor Healthcare Is

Primary Sidebar

Subscribe to our newsletter

Icon

A Black Women's Guide To Beating Breast Cancer

1 file(s) 967 KB
Download

Trending Articles

Doctors Dismissed Her Symptoms—Then She Collapsed at a Work Conference

lupus

Sit Fit: 5 Leg & Thigh Exercises You Can Do Sitting Down

chair exercises

How I Advocated For Myself to Join a Breast Cancer Clinical Trial

How I Advocated For Myself to Join a Breast Cancer Clinical Trial

This Study Reveals Why More People Aren’t Doing Clinical Trials

This Study Reveals Why More People Aren't Doing Clinical Trials

7 Best Kept Secrets For Weight Loss

weight loss
Find a Culturally Sensitive Doctor

Footer

Where Wellness & Culture Connect

BDO is the world’s largest and most comprehensive online health resource specifically targeted to African Americans. BDO understands that the uniqueness of Black culture - our heritage and our traditions - plays a role in our health. BDO gives you access to innovative new approaches to the health information you need in everyday language so you can break through the disparities, gain control and live your life to its fullest.

Connect With Us

Resource Centers

  • Top Blacks in Healthcare
  • Clinical Trials
  • Wellness on the Yard
  • Cancer
  • Immunocompromised Care
  • About Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Service
  • Careers
  • Advertise With Us
  • Advertising & Sponsorship Policy
  • Daily Vitamina
  • TBH

Copyright © 2025, Black Doctor, Inc. All rights reserved.